vs

Side-by-side financial comparison of Moderna (MRNA) and SUN COMMUNITIES INC (SUI). Click either name above to swap in a different company.

Moderna is the larger business by last-quarter revenue ($1.0B vs $697.2M, roughly 1.5× SUN COMMUNITIES INC). SUN COMMUNITIES INC runs the higher net margin — 1.7% vs -19.7%, a 21.4% gap on every dollar of revenue. On growth, SUN COMMUNITIES INC posted the faster year-over-year revenue change (-25.8% vs -45.4%). Over the past eight quarters, SUN COMMUNITIES INC's revenue compounded faster (-2.1% CAGR vs -45.0%).

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

Sun Communities is a publicly traded real estate investment trust that invests in manufactured housing communities and recreational vehicle communities. As of June 2, 2025, the company owned interests in 500 such properties in the United States, Canada, and the UK..

MRNA vs SUI — Head-to-Head

Bigger by revenue
MRNA
MRNA
1.5× larger
MRNA
$1.0B
$697.2M
SUI
Growing faster (revenue YoY)
SUI
SUI
+19.6% gap
SUI
-25.8%
-45.4%
MRNA
Higher net margin
SUI
SUI
21.4% more per $
SUI
1.7%
-19.7%
MRNA
Faster 2-yr revenue CAGR
SUI
SUI
Annualised
SUI
-2.1%
-45.0%
MRNA

Income Statement — Q3 FY2025 vs Q2 FY2026

Metric
MRNA
MRNA
SUI
SUI
Revenue
$1.0B
$697.2M
Net Profit
$-200.0M
$12.1M
Gross Margin
79.6%
Operating Margin
-25.6%
Net Margin
-19.7%
1.7%
Revenue YoY
-45.4%
-25.8%
Net Profit YoY
-1638.5%
-96.0%
EPS (diluted)
$-0.51
$0.07

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MRNA
MRNA
SUI
SUI
Q3 25
$1.0B
$697.2M
Q2 25
$623.5M
Q1 25
$470.2M
Q4 24
$966.0M
$745.9M
Q3 24
$1.9B
$939.9M
Q2 24
$864.0M
Q1 24
$671.3M
Q4 23
$2.8B
$726.7M
Net Profit
MRNA
MRNA
SUI
SUI
Q3 25
$-200.0M
$12.1M
Q2 25
$1.3B
Q1 25
$-41.2M
Q4 24
$-1.1B
$-228.4M
Q3 24
$13.0M
$300.5M
Q2 24
$56.7M
Q1 24
$-25.2M
Q4 23
$217.0M
$-429.7M
Gross Margin
MRNA
MRNA
SUI
SUI
Q3 25
79.6%
Q2 25
Q1 25
Q4 24
23.5%
Q3 24
72.4%
Q2 24
Q1 24
Q4 23
67.0%
Operating Margin
MRNA
MRNA
SUI
SUI
Q3 25
-25.6%
Q2 25
Q1 25
Q4 24
-129.0%
Q3 24
-3.8%
Q2 24
Q1 24
Q4 23
0.2%
Net Margin
MRNA
MRNA
SUI
SUI
Q3 25
-19.7%
1.7%
Q2 25
210.8%
Q1 25
-8.8%
Q4 24
-115.9%
-30.6%
Q3 24
0.7%
32.0%
Q2 24
6.6%
Q1 24
-3.8%
Q4 23
7.7%
-59.1%
EPS (diluted)
MRNA
MRNA
SUI
SUI
Q3 25
$-0.51
$0.07
Q2 25
$10.02
Q1 25
$-0.34
Q4 24
$-2.91
$-1.80
Q3 24
$0.03
$2.31
Q2 24
$0.42
Q1 24
$-0.22
Q4 23
$0.63
$-3.51

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MRNA
MRNA
SUI
SUI
Cash + ST InvestmentsLiquidity on hand
$1.1B
$542.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$9.3B
$7.0B
Total Assets
$12.1B
$12.8B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MRNA
MRNA
SUI
SUI
Q3 25
$1.1B
$542.7M
Q2 25
$889.7M
Q1 25
Q4 24
$1.9B
$47.4M
Q3 24
$1.6B
Q2 24
Q1 24
Q4 23
$2.9B
$29.2M
Total Debt
MRNA
MRNA
SUI
SUI
Q3 25
Q2 25
Q1 25
Q4 24
$7.4B
Q3 24
Q2 24
Q1 24
Q4 23
$7.8B
Stockholders' Equity
MRNA
MRNA
SUI
SUI
Q3 25
$9.3B
$7.0B
Q2 25
$7.4B
Q1 25
$6.9B
Q4 24
$10.9B
$7.1B
Q3 24
$11.9B
$7.5B
Q2 24
$6.9B
Q1 24
$6.9B
Q4 23
$13.9B
$7.1B
Total Assets
MRNA
MRNA
SUI
SUI
Q3 25
$12.1B
$12.8B
Q2 25
$13.4B
Q1 25
$16.5B
Q4 24
$14.1B
$16.5B
Q3 24
$15.8B
$17.1B
Q2 24
$17.0B
Q1 24
$17.1B
Q4 23
$18.4B
$16.9B
Debt / Equity
MRNA
MRNA
SUI
SUI
Q3 25
Q2 25
Q1 25
Q4 24
1.04×
Q3 24
Q2 24
Q1 24
Q4 23
1.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MRNA
MRNA
SUI
SUI
Operating Cash FlowLast quarter
$-847.0M
$197.8M
Free Cash FlowOCF − Capex
$-880.0M
FCF MarginFCF / Revenue
-86.6%
Capex IntensityCapex / Revenue
3.2%
Cash ConversionOCF / Net Profit
16.35×
TTM Free Cash FlowTrailing 4 quarters
$-1.9B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MRNA
MRNA
SUI
SUI
Q3 25
$-847.0M
$197.8M
Q2 25
$256.0M
Q1 25
$243.9M
Q4 24
$825.0M
$118.0M
Q3 24
$-1.6B
$189.2M
Q2 24
$311.3M
Q1 24
$242.5M
Q4 23
$622.0M
$117.6M
Free Cash Flow
MRNA
MRNA
SUI
SUI
Q3 25
$-880.0M
Q2 25
Q1 25
Q4 24
$303.0M
Q3 24
$-1.7B
Q2 24
Q1 24
Q4 23
$402.0M
FCF Margin
MRNA
MRNA
SUI
SUI
Q3 25
-86.6%
Q2 25
Q1 25
Q4 24
31.4%
Q3 24
-92.2%
Q2 24
Q1 24
Q4 23
14.3%
Capex Intensity
MRNA
MRNA
SUI
SUI
Q3 25
3.2%
Q2 25
Q1 25
Q4 24
54.0%
Q3 24
8.1%
Q2 24
Q1 24
Q4 23
7.8%
Cash Conversion
MRNA
MRNA
SUI
SUI
Q3 25
16.35×
Q2 25
0.19×
Q1 25
Q4 24
Q3 24
-120.46×
0.63×
Q2 24
5.49×
Q1 24
Q4 23
2.87×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MRNA
MRNA

COVID19$971.0M96%
Other Revenue$20.0M2%
Grant$14.0M1%
Collaboration Arrangement Including Arrangements With Affiliate$7.0M1%
License And Royalty$2.0M0%

SUI
SUI

Segment breakdown not available.

Related Comparisons